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AbstrACt
Introduction Advances in antiretroviral therapy have 
transformed HIV into a long-term condition with near-
normal life expectancy for those in whom viral replication 
is well controlled on treatment. This means that age-
related events, including menopause, is of increasing 
importance in the care of people living with HIV. The PRIME 
(Positive Transitions Through the Menopause) Study aims 
to explore the impact of the menopause on the health and 
well-being of women living with HIV (WLHIV).
Methods and analysis The PRIME Study is a multicentre, 
mixed-methods observational study deploying a 
multiphase sequential design with explanatory and 
exploratory phases. Phase 1 comprised three focus 
group discussions with WLHIV. In phase 2 we aimed to 
administer questionnaires comprising detailed assessment 
of menopausal status and symptoms to 1500 WLHIV 
aged 45–60 attending HIV clinics in England. Phase 3 
comprised semistructured interviews with a subsample 
of phase 2 participants. Ongoing quantitative follow-up of 
100 participants is planned between October 2018 and 
September 2019. Qualitative and quantitative data will be 
kept analytically distinct and analysed using appropriate 
methods. We will integrate quantitative and qualitative 
findings using coding matrices.
Ethics and dissemination The PRIME Study has ethical 
approval from the South East Coast-Surrey Research 
Ethics Committee on behalf of all National Health 
Service (NHS) sites, and approval from University College 
London Research Ethics Committee for qualitative work 
conducted in non-NHS sites. In conjunction with the 
study Expert Advisory Group (which includes WLHIV), we 
have drafted a dissemination strategy that takes into 
account a wide range of stakeholders, including patients, 
policy makers and healthcare providers. This includes at 
least five empirical research papers to be submitted to 
peer-reviewed journals, as well as an accessible report 
aimed primarily at a non-technical audience (published in 
May 2018 and launched at a live-streamed event). Both 
quantitative and qualitative data are held by the PRIME 
Study team and are available by request.
IntroduCtIon
Advances in antiretroviral therapy (ART) have 
transformed HIV into a long-term condition 
with near-normal life expectancy for those in 
whom viral replication is well controlled on 
treatment.1 Consequently, this is leading to a 
shift in the age distribution of people living 
with HIV (PLHIV), with nearly two-fifths of 
people accessing HIV care in the UK aged 50 
or over.2 
Approximately 10 500 women of poten-
tially menopausal age (45–56 years) 
attended for HIV care in the UK in 2016, 
a fivefold increase over a 10-year period 
(Z Yin, Public Health England, personal 
communication, 3 October 2017). Based on 
the age distribution of women attending for 
HIV care in the UK in 2013, a further 10 000 
strengths and limitations of this study
 ► A key strength of the PRIME (Positive Transitions 
Through the Menopause) Study lies in its combina-
tion of quantitative and qualitative data on reproduc-
tive ageing in women living with HIV.
 ► Linking to clinical records (with consent) provides 
further robust data on clinical outcomes.
 ► Patient and public involvement is core to the PRIME 
Study, with women living with HIV involved in study 
design, recruitment, data collection, data analyses 
and dissemination.
 ► In recruiting solely from National Health Service 
sites in phases 2 and 3, we will have excluded wom-
en who are not engaged in HIV care, whose needs 
and experiences may differ.
 ► The cross-sectional nature of the baseline PRIME 
Study means we are unable to infer causality in 
the  analyses of these data; however, longitudinal 
follow-up is ongoing for a subgroup of participants.
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are likely to reach menopausal age by 2023.3 Globally 
over half of the 36.7 million PLHIV internationally are 
female,4 and the proportion of those aged 50 years and 
older is increasing.5 Age-related events (including the 
menopause) are therefore of increasing importance in 
the clinical care of women living with HIV (WLHIV).
Natural menopause occurs at a median age of 51 years 
in the UK,6 with two-thirds of women reporting symp-
toms such as hot flushes, sleep disturbance and mood 
changes,7 lasting a median duration of 7.4 years.8 These 
symptoms are known to impact women’s quality of life 
(QoL), work performance and social lives; over half of 
the respondents in a recent British survey reported that 
the menopause had negatively impacted their lives.9
Women living with long-term conditions, such as HIV, 
may experience particular challenges during the meno-
pause transition as a result of having to manage meno-
pausal symptoms in the context of other symptoms 
related to their long-term condition. However there are 
few data concerning the impact of the menopause in 
these populations.10
Existing data on menopause in WLHIV are scarce and 
often contradictory. There is no clear consensus on the 
impact of HIV status on age at menopause11; however, 
there is evidence that suggests that WLHIV experience a 
greater burden of menopausal symptoms than HIV-neg-
ative women, including vasomotor symptoms, sexual 
dysfunction and mood changes.11 Furthermore, it is clear 
that WLHIV are at increased risk (compared with both 
HIV-negative women and HIV-positive men) of devel-
oping comorbid conditions such as osteoporosis and 
cardiovascular disease as a result of the synergistic effects 
of HIV and oestrogen depletion.12 13
However, there remain limited data on the meno-
pause in WLHIV.14 Much of the available data come 
from the USA and South America. Findings from these 
studies may not be applicable in settings such as sub-Sa-
haran Africa and Europe, where patient cohorts differ 
in terms of ethnicity, comorbid conditions, substance 
misuse, socioeconomic status and healthcare access. 
There are limited or no data on the following in WLHIV: 
the impact of the menopause transition on QoL, sexual 
function, mental health, adherence to ART and reten-
tion in HIV care; the use of hormone replacement 
therapy (HRT) and other treatments; and the poten-
tial role of psychosocial interventions. Furthermore, 
there has been no qualitative research to date focusing 
on the lived experiences of reproductive ageing among 
WLHIV.
In response to these identified gaps in evidence, the 
PRIME Study (Positive Transitions Through the Meno-
pause; www. ucl. ac. uk/ prime- study) was designed to 
explore, for the first time in the UK, the impact of the 
menopause transition on the health and well-being of 
WLHIV.
The following are the specific research questions:
1. What is the prevalence of menopause (stratified by 
age) and menopausal symptoms among WLHIV?
2. What factors are associated with earlier age at meno-
pause and increased menopausal symptoms in WL-
HIV?
3. Among WLHIV, what is the association between both 
menopausal status and symptoms, and (a) mental 
health, (b) sexual function, (c) QoL, (d) adherence to 
ART and (e) retention in HIV care?
4. What are the lived experiences of the menopause tran-
sition among WLHIV?
5. What is the current management of menopausal symp-
toms among WLHIV in the UK?
MEthods And AnAlysIs
overall study design
The PRIME Study is an ongoing, longitudinal, mixed-
methods observational study of the impact of the 
menopause transition on the health and well-being of 
WLHIV. Mixed-methods research ‘focuses on collecting, 
analysing, and mixing both quantitative and qualita-
tive data in a single study or a series of studies’.15 The 
underlying assumption of mixed-methods research is 
that it has the potential to address some research ques-
tions more comprehensively than by using either quan-
titative or qualitative methods alone.15 We acknowledge 
the different epistemologies associated with quantitative 
and qualitative research, but draw on the philosophical 
tenets of pragmatism when seeking to combine these 
approaches.16
Nearly two-thirds of WLHIV in the UK are of black 
African ethnicity.2 Understanding the impact of the 
menopause on health and well-being in an ethnically 
diverse population of WLHIV involves exploring clin-
ical outcomes, individual beliefs about the menopause, 
the cultural construction of the postreproductive female 
body and lived experiences. The complex and multidi-
mensional nature of the menopause disrupts a simple 
dichotomy of quantitative and qualitative methodologies, 
instead requiring an integration of both. The PRIME 
Study therefore draws on public health approaches to 
population health, and also medical anthropology, in 
particular the anthropology of gender and reproduction, 
in order to address our overall research question.
This work is theoretically informed by the concept of 
intersectionality, an analytic framework that seeks to under-
stand how multiple social categories (in this case gender, 
ethnicity, age, menopausal status and HIV status) combine 
and intersect to shape experience and disadvantage.17
In this paper, we focus on the design of the baseline 
study and planned longitudinal follow-up. We have 
deployed a multiphase sequential mixed-methods study 
design (figure 1), combining exploratory and explana-
tory phases, with equal weight given to both quantitative 
and qualitative approaches. Baseline data collection has 
occurred in three phases (table 1), with some overlap due 
to time constraints.
Phase 1 was qualitative, comprising focus group discus-
sions (FGDs) with WLHIV aged 45 and over, primarily to 
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inform the design of the quantitative questionnaire and 
semistructured interview (SSI) schedule (phases 2 and 3, 
respectively).
Phase 2 was quantitative, comprising a questionnaire 
study of WLHIV aged between 45 and 60 years attending 
for HIV care in England, collecting data on meno-
pausal status, menopausal symptomatology and key clin-
ical outcomes quantitatively. This was complemented 
by linkage to clinical data records (with participant 
consent). Prior to administering the quantitative ques-
tionnaire (phase 2), we conducted cognitive interviews 
with three WLHIV aged between 45 and 60 who were 
recruited via word of mouth through our existing profes-
sional networks (and who had not participated in phase 
1). This qualitative approach allowed us to evaluate ques-
tionnaire items in terms of comprehension and question 
interpretation, information retrieval and response elicita-
tion, refining questions where necessary.18
Phase 3 was qualitative and comprised semistructured 
qualitative interviews with a subsample of women who 
participated in the phase 2 questionnaire study. This 
sequential design allows quantitative findings to be 
contextualised, while providing deeper understanding 
of the lived experiences of the menopause transition in 
WLHIV.
setting
In phase 1, we recruited WLHIV through Positively UK, 
the UK’s leading HIV peer-support charity which is based 
in London, to participate in FGDs.
For the questionnaire and SSI study (phases 2 and 3), 
we recruited women attending one of the 21 National 
Figure 1 Overview of the PRIME Study design. PRIME, Positive Transitions Through the Menopause; SSIs, semistructured 
interviews. 
Table 1 Study phases and their relation to research questions among women living with HIV
Research question Phase Sample Data
1. Prevalence of menopausal status and symptoms. 1 Questionnaire participants (clinic), n=869 Questionnaire
2. Factors associated with age at menopause and 
symptoms.
1 Questionnaire participants (clinic), n=869 Questionnaire
Clinical data
3. Association between both menopausal status and 
symptoms, and mental health, sexual function, QoL, 
adherence to ART and retention in HIV care.
1–3 Community participants (HIV charity), 
n=24 (3 FGDs)
Questionnaire participants (clinic), n=869
SSI participants (clinic), n=20
FGD
Questionnaire
SSI
4. Lived experiences of the menopause. 1 and 3 Community participants (HIV charity), 
n=24 (3 FGDs)
SSI participants (clinic), n=20
FGD
SSI
5. Current management of menopausal symptoms. 1–3 Community participants (HIV charity), 
n=24 (3 FGDs)
Questionnaire participants (clinic), n=869
SSI participants (clinic), n=20
FGD
Questionnaire
SSI
ART, antiretroviral therapy; FGD, focus group discussion; QoL, quality of life; SSI, semistructured interview.
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Health Service (NHS) clinics in England for HIV care. 
HIV care is available free of charge in the UK through 
specialist HIV clinics, and is where the overwhelming 
majority of PLHIV receive specialist care. We selected 
sites known to have large numbers of female patients in 
this age group (almost all of them in London) and sites 
that allowed for geographical diversity within England (G 
Rooney, Public Health England, personal communica-
tion, 13 February 2015).
Phase 1: qualitative (FGds)
The aim of phase 1 was to inform the design of the phase 
2 questionnaire and phase 3 SSI schedule.
Eligibility
In partnership with Positively UK, we invited WLHIV 
aged 45 and over (regardless of menopausal status) to 
participate in FGDs (purposive sampling). Women who 
did not speak English were unable to participate in FGDs. 
Working with two peer researchers (both WLHIV aged 
over 45), we approached Positively UK service users 
through advertising at Positively UK (by poster and flyers) 
and direct phone or face-to-face contact.
Data collection
The first author (ST) conducted all FGDs on charity prem-
ises between June and August 2015, with peer researchers 
cofacilitating. Focus groups can be particularly useful in 
identifying group norms, exploring areas of consensus 
and dissent, and discussing potentially sensitive subjects 
(such as the menopause), especially among margin-
alised groups.19 Topics explored included knowledge 
and experiences of the menopause (using a pile-sorting 
exercise to ascertain commonly experienced symptoms); 
language used to describe menopause and menopausal 
symptoms; care-seeking and self-management; and the 
impact of the menopause on their experience of living 
with HIV (and vice versa) (table 2). We also asked partic-
ipants to comment on selected sections of a draft ques-
tionnaire (comprising validated questions obtained 
through an initial scoping review). This allowed us to 
ascertain whether questions were readily understood, 
easy to complete and acceptable to participants (this was 
particularly the case with sensitive questions such as about 
sexual function). This resulted in important changes. For 
instance, FGD data revealed that the term menopause 
Table 2 Focus group discussion and semistructured interview schedule
Focus group discussion questions Semistructured interview questions
1. Can you share what you understand about what 
happens to women’s periods as they get older?
1. What do you understand by the word menopause?
2. What happens to women’s health as their 
periods begin to stop?
2. Could you share any experiences you have of the menopause either 
personally or from other people?
3. What do you understand by the word 
menopause?
3. If perimenopausal or postmenopausal:
 ► How has life changed since the menopause (if at all)?
 ► How have you managed through this phase of life?
 ► How prepared did you feel for this phase of life?
 ► How do you think your experience of the menopause might be different 
from a woman without HIV?
 ► What is it like managing HIV through this phase of life?
4. Pile-sorting exercise: menopausal symptoms. 4. If premenopausal:
 ► What do you expect to happen to you during the menopause?
 ► How do you think life might change during this phase of life (if at all)?
 ► How prepared do you feel for this phase of life?
 ► How do you think experiences of the menopause might be different from 
a woman without HIV?
 ► How are you managing with HIV at the moment?
5. Could you share any experiences you have of 
the menopause either personally or things you 
have heard from other people?
5. All women:
 ► What could be done to help women during the menopause?
 ► Do women living with HIV need specific help, and if so what?
 ► Where do you think women living with HIV would like to go for help?
6. If you had physical or emotional symptoms 
around this time, what could you do about it?
7. Do you think the menopause and HIV affect 
each other?
8. As you know we are doing some research on 
women living with HIV as they go through the 
menopause (when their periods stop as they 
older). What kind of things do you think we should 
be looking at?
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was either not familiar to participants or had a variety 
of meanings. This allowed us to clarify the term in the 
final questionnaire. We also asked participants to high-
light areas we had overlooked, for example, use of herbal 
remedies and the importance of social support. Each 
FGD lasted between 90 and 120 min, and was audio-re-
corded and transcribed verbatim.
Sample size
Three FGDs (comprising 24 women in total, comprising 
6–10 participants in each group) were deemed feasible 
within our timeframe and sufficient to achieve our aim.
Phase 2: quantitative (questionnaires with linkage to clinical 
data)
The aim of phase 2 was to explore age at menopause, and 
the association between menopausal status and symptom-
atology, and key outcomes (objectives 1–3, and 5).
We conducted cognitive interviews with three WLHIV 
aged between 45 and 60 recruited from Positively UK 
and via the UK-CAB (the UK’s HIV treatment advocate 
network) to inform questionnaire development. These 
interviews were conducted face-to-face by ST, audio-re-
corded and transcribed verbatim. We then proceeded to 
administer the questionnaires.
Eligibility
Between January 2016 and June 2017, local clinical 
care teams recruited WLHIV (defined as female sex at 
birth for the purposes of this study) aged between 45 
and 60 attending for HIV care at one of the 21 partici-
pating sites. Women were eligible to participate regard-
less of menopausal status. Women were ineligible if they 
had experienced surgical menopause or had a history of 
anything that might disrupt their bleeding pattern, such 
as hysterectomy; congenital absence of uterus and/or 
both ovaries; pregnancy or breast feeding within the last 
12 months, and hormonal contraception within the last 
6 months for either contraceptive or non-contraceptive 
use (women commencing intrauterine system as part of 
HRT were eligible); and chemotherapy or radiotherapy 
within the last 6 months. We also excluded women 
whose last menstrual period was more than 60 months 
prior (unless currently on HRT) as we aimed to capture 
women who were most likely to be experiencing symp-
toms. Women were not eligible if they were unable to give 
informed consent.
Data collection
We administered self-completed paper questionnaires 
in English to all participants, taking approximately 
15–30 min to complete. Participants were encouraged 
to complete the questionnaire within the clinic (with a 
private room offered to all participants); a minority chose 
to complete the questionnaire at home and return it by 
post. In cases of poor literacy or non-English speakers, 
participants were offered the opportunity to complete the 
questionnaire via a face-to-face interview, with the assis-
tance of an interpreter (if required). The questionnaire 
comprised 51 questions (subject to skip logic) divided into 
5 sections: participant demographics; medical history and 
lifestyle factors; HIV-related history; menopausal status, 
symptoms and care-seeking; and sexual function. Where 
possible we used validated tools including the Menopause 
Rating Scale (MRS),20 the Patient Health Questionnaire 
4,21 EuroQoL 5D (EQ-5D),22 the National Survey of Sexual 
Attitudes and Lifestyle Sexual Function measure,23 and 
the Hot Flash-Related Daily Interference Scale.20 Meno-
pausal status was determined from self-reported menstrual 
pattern (without biological confirmation), an approach 
that has been validated.24 We categorised menopausal 
status according to the modified Stages of Reproductive 
Aging Workshop (STRAW) +10 criteria, internationally 
accepted staging criteria for menopausal status designed 
to facilitate comparability across studies.25 With partic-
ipants’ consent, questionnaire data were supplemented 
by routinely collected clinical data, including nadir and 
current CD4 count, baseline and current HIV viral load, 
and current ART regimen.
Sample size
The recruitment target was 1500 women (500 premeno-
pausal, 500 perimenopausal and 500 postmenopausal). 
For primary outcomes, the key exposure variables 
are premenopausal status versus menopausal status 
(including both perimenopausal and postmenopausal 
women, where you would expect the greatest prevalence 
of menopausal symptoms). A sample size of 1500 provides 
at least 95% power at a 5% level of significance to compare 
key outcomes of interest, based on a ±10% difference 
from prevalence estimates from previous studies. For 
example adherence to ART among PLHIV in the UK is 
estimated to be 80%.26 If we assume a rate of adherence 
to ART in the premenopausal group of 80% and 70% in 
the menopausal group, power will be >95%. Looking at a 
different outcome, if we assume a prevalence of depres-
sion of 25% in the premenopausal group27 and 35% in 
the menopausal group, we will have 80% power to detect 
a difference.
Phase 3: qualitative (ssIs)
Eligibility
Women who completed the questionnaire in phase 2 
and who gave consent to be contacted about a qualita-
tive interview were contacted by telephone by ST and 
invited to participate in an SSI. Due to feasibility, women 
were only recruited from London sites. Sampling was 
purposive in that we recruited women of premenopausal, 
perimenopausal and postmenopausal status in order to 
reflect different stages of the menopause transition.
Data collection
All SSIs were conducted by ST face-to-face in a private 
room on hospital or university premises between April 
2016 and April 2018. ST is a female doctor and public 
health academic in her early 40s and is of British Pakistani 
ethnicity. Topics explored during SSIs include knowledge, 
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expectations and experiences of the menopause; cultural 
attitudes towards the menstruation and menopause; 
management of menopausal symptoms; impact of the 
menopause on health and well-being (including HIV 
care); and recommendations for interventions and 
service improvement (table 2). We also used graphic elic-
itation, asking women to represent their symptoms on a 
diagram of the body (figure 2). Graphic elicitation, the 
use of diagrams in interviews as stimuli, can yield data 
that may otherwise be difficult to obtain through verbal 
exchange, such as the experience of symptoms.28 All SSIs 
were audio-recorded and transcribed verbatim.
Sample size
A total of 20 women participated in SSIs, at which point 
data saturation was reached.
data analysis
Quantitative data analysis
Estimates of menopause prevalence stratified by age 
will be obtained using Kaplan-Meier plots, in which the 
cumulative proportion of participants who are postmeno-
pausal will be plotted by age. Cox regression will be used 
to explore factors associated with age at menopause, 
such as nadir CD4 count. For analyses of associations 
between key outcomes and (1) menopausal status and 
(2) menopausal symptoms, we will use χ2 tests and t-tests 
(or a non-parametric equivalent) to compare character-
istics in each group, followed by multivariable logistic 
regression modelling. We define menopausal status 
according to the modified STRAW+10 criteria25 as follows: 
premenopausal (menses within the past 3 months, no 
interval of amenorrhoea for ≥60 days in the past 6 months 
and no late period in the past 2 years); perimenopausal 
(menses within the past 12 months but an interval of 
amenorrhoea for ≥60 days in the past 6 months and/or 
a late period in the past 2 years); and postmenopausal 
(amenorrhoea for ≥12 months). Menopausal symptoms 
will be captured using the MRS and categorised according 
to standard cut-offs.20
Qualitative data analysis
We will analyse FGD and SSI data thematically, using 
an integrated approach that includes both inductive 
development of codes as well as a deductive organising 
framework (derived from results from the quantitative 
analyses).29 This will facilitate integration of quantitative 
and qualitative data. For instance, if low sexual function is 
noted to be prevalent among women of postmenopausal 
status, then we will interrogate our qualitative data sets 
to explore attitudes towards or experiences of reduced 
sexual function among participants. Transcripts will be 
read several times with sections coded. Coded text will 
then be compared and linked across other interviews if 
they capture similar themes, leading to the development 
of broader key categories.
Mixed-methods data integration
This study draws on quantitative data from question-
naires and qualitative data from FGDs and SSIs. In 
order to maximise the potential of this rich mixed-
methods data set, we will integrate findings from each 
data source, following analyses of quantitative and qual-
itative data. This will allow us to contextualise findings, 
identify areas of discrepancy and generate new hypoth-
eses. Quantitative and qualitative data will be kept 
analytically distinct and analysed using the approaches 
outlined above. We will primarily integrate findings 
using convergence code matrices (table 3).30 This approach 
allows us to triangulate findings from each phase of 
the study in relation to each specific research objec-
tive, highlighting areas of agreement, disagreement or 
silence (in cases where one data set makes no reference 
to this objective). Furthermore, as we will have both 
quantitative and qualitative data on a subset of partic-
ipants (those who participated in an SSI), we will be 
able to construct mixed-methods cases,31 using matrices 
to visualise quantitative and qualitative data from each 
participant on menopausal symptoms, mental health, 
sexual function, QoL, adherence to ART and retention 
in HIV care (table 4).
This again will allow us to explore similarities and 
discrepancies in data from each participant, as well as 
to identify patterns across individuals. Understanding 
areas of complementarity and divergence in our mixed-
methods data set is critical in gaining further insight into 
findings.
Figure 2 Example of graphic elicitation of menopausal 
symptoms from a participant.
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longitudinal follow-up
In October 2018, we will undertake a follow-up study of 100 
PRIME participants. We aim to describe levels of follicle 
stimulating hormone (FSH) in WLHIV aged >45 who 
were categorised as perimenopausal at baseline and who 
now report amenorrhoea for ≥12 months (and therefore 
would be categorised at postmenopausal). FSH levels 
in the general population increase significantly from 
premenopause to postmenopause.32 However, national 
guidelines advise that in women aged >45 years, meno-
pause is a clinical diagnosis, established after 12 or more 
months of amenorrhoea in those with an intact uterus 
and not using hormonal contraception.6 Disordered 
menstrual function and prolonged amenorrhoea (in the 
absence of biological markers of ovarian failure) have 
been reported in HIV, but in older studies comprising 
women who were diagnosed with advanced HIV and had 
limited access to ART.33 Data on FSH levels from our longi-
tudinal follow-up will allow us to confirm if menstrual 
history in WLHIV aged 45–60 is sufficient for diagnosing 
menopause in the contemporary ART era.
We will recruit 100 PRIME participants who were 
categorised as perimenopausal at entry into the cohort 
(between January 2016 and June 2017), who provided 
consent for ongoing contact about PRIME-related studies 
and who now report ≥12 months amenorrhoea. We will 
administer a short self-completed paper questionnaire 
(to ascertain menopausal symptoms and mental health), 
collect data on HIV viral load from clinical databases and 
take a serum sample to measure FSH.
A previous study of FSH in postmenopausal women 
(without HIV) demonstrated that the 25th centile for 
FSH in this group was 30 mIU/mL.32 Cejtin et al,34 in their 
study of FSH levels in WLHIV aged 16–55 with amenor-
rhoea, revealed a prevalence of elevated FSH (defined 
as >25 mIU/mL) of 47%. We therefore believe 60% to be 
a pragmatic and conservative estimate of prevalence of 
elevated FSH in this age group. Based on this estimated 
prevalence, a sample size of 96 will allow us to obtain an 
estimate with 10% precision.
Patient and public involvement
We are committed to the meaningful involvement of 
WLHIV at all stages of the research process35 and have 
drawn on National Institute for  Health Research (NIHR) 
INVOLVE guidance.36 The study proposal was discussed 
and reviewed by WLHIV. We recruited three community 
representatives (all WLHIV aged 45 or over) to sit on 
our Expert Advisory Group via the UK-CAB, alongside 
academics and clinicians. The community representatives 
provide insight and expertise into the design, conduct, 
dissemination and development of the study. Two of 
the community representatives also worked as peer 
researchers in phase 1 of the study, providing invaluable 
expertise in recruitment, facilitation of focus groups and 
analysis of data.
EthICs And dIssEMInAtIon
Written informed consent has been obtained from partic-
ipants in all phases of the baseline study. We have also 
sought consent from baseline questionnaire participants 
to contact them in the future about other studies related 
to the PRIME Study. SSI and FGD (but not question-
naire) participants were reimbursed with a £20 shopping 
voucher in recognition of their time.
Table 3 Example of convergence coding matrix for quantitative and qualitative data collection
Impact of menopausal symptoms on QUANT findings QUAL findings
Integrated findings 
(agreement/partial agreement/
silence/disagreement)
Mental health
Sexual function
Quality of life
Adherence to antiretroviral therapy
Retention in HIV care
QUAL, qualitative; QUANT, quantitative.
Table 4 Example of convergence coding matrix for analysing quantitative and qualitative data within and across individual 
participants
Participant ID
QUANT: psychological 
distress (PHQ-4 >3)
QUAL: impact of menopausal 
symptoms on mental health
QUANT: menopause 
care-seeking
QUAL: menopause 
care-seeking
1
2
3
PHQ-4, Patient Health Questionnaire 4; QUAL, qualitative; QUANT, quantitative.
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Quantitative and qualitative data collected during the 
study are not open access. However, they can be made 
available by request to the study team. In conjunction 
with the Expert Advisory Group, we have established 
a clear dissemination strategy that takes into account a 
wide range of stakeholders including WLHIV. A publica-
tion plan includes presentation at scientific conferences 
and peer-reviewed publications (at least five empirical 
papers). Where possible, we will present quantitative and 
qualitative data together, drawing on the Good Reporting 
of a Mixed Methods Study framework.37 We have synthe-
sised initial study findings in an accessible report aimed 
primarily at a non-technical audience. This report was 
launched at a live-streamed dissemination event aimed at 
key stakeholders including WLHIV. Finally, throughout 
the study, we have been highlighting progress and emer-
gent findings through our study website ( www. ucl. ac. uk/ 
prime- study) and study Twitter account (@PRIME_UCL).
dIsCussIon
This ongoing mixed-methods observational study 
comprising FGDs, questionnaires and SSIs aims to 
examine the impact of menopause on the health and 
well-being of WLHIV. It was designed in response to a 
recognised paucity of data in this growing patient group.
limitations
Our original target recruitment number for phase 2 
was 1500 WLHIV, based on an ineligibility rate of 10%. 
Despite an uptake of 80% among women approached, we 
were not able to reach this target due to a much higher 
ineligibility rate than anticipated. In total, 1999 women 
were approached, of whom 1312 (65.6%) were eligible 
to participate. Of these eligible women, 1059 (80.7%) 
consented to participate; we have completed question-
naires on 869 women. However, a sample size of 869 
still provides at least 80% power at a 5% level of signif-
icance to compare key outcomes of interest, based on 
a ±10% difference from prevalence estimates.
We are aware of the potential for selection bias; however, 
it is hard to predict whether women with increased meno-
pausal symptoms would be more or less likely to partici-
pate in the study. In recruiting solely from NHS sites in 
phases 1 and 2, we will have excluded the minority of 
women who are not engaged in HIV care, whose needs 
and experiences may differ. In recruiting women aged 
between 45 and 60, we will not have data on those who 
have experienced premature ovarian insufficiency (meno-
pause aged <40 years). One of our exclusion criteria is use 
of hormonal contraception, which may have led to sexu-
ally active women being more likely to be excluded. Of 
those who were ineligible and on whom we have data on 
ineligibility, 23% were on hormonal contraception. The 
most common reason for ineligibility was last menstrual 
period more than 60 months prior.
In terms of study design, the cross-sectional nature of 
the baseline PRIME Study means we are unable to infer 
causality in analyses of these quantitative data. Finally, the 
lack of an HIV-negative comparison group prevents us 
from looking at the impact of HIV status on the experi-
ence of menopause. However, in future work we plan to 
explore ways of recruiting a similarly aged and ethnically 
diverse group of HIV-negative women.
strengths
A key strength of the PRIME Study lies in its combina-
tion of quantitative and qualitative data on reproductive 
ageing in WLHIV. This mixed-methods approach will 
allow us to address our research questions more compre-
hensively than had we used either quantitative or quali-
tative methods alone. Having recruited 869 participants 
in phase 2, with ongoing qualitative data collection in a 
subset of these women, the PRIME Study is already the 
largest study of menopause in WLHIV in Europe and one 
of the largest globally. We have recruited women from 
clinics across England, which means study findings are 
likely to be generalisable nationally. The questionnaire 
was designed in discussion with ongoing women’s cohort 
studies in North America and with the Third National 
Survey of Sexual Attitudes and Lifestyles, a national 
probability sample survey of sexual behaviour and atti-
tudes in England. This has allowed us to incorporate vali-
dated tools used in these other studies, enabling future 
combined analyses. Finally, we will be following a subset 
of PRIME participants longitudinally from October 2018, 
with further longitudinal follow-up planned in the future 
subject to funding.
ConClusIon
Increasing availability and effectiveness of ART means 
that a growing number of WLHIV will be reaching mid-life 
and beyond, both in the UK and globally. The needs 
of WLHIV transitioning through the menopause are 
currently poorly understood. The PRIME Study is there-
fore timely in its focus on the menopause in this patient 
population. We anticipate that our study findings will 
produce new insights into how the menopause impacts 
their health and well-being, informing the commissioning 
and provision of services for WLHIV across the life course.
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